Epithalon: the telomere peptide, and the fine print

The short version: Epithalon, also spelt Epitalon, is a synthetic peptide of just four amino acids: alanine, glutamic acid, aspartic acid and glycine. It was designed from the make-up of epithalamin, an extract of cattle pineal glands. Its reputation rests on telomeres, the protective caps on the ends of chromosomes. Most of the research comes from one Russian group, most of it is in cells and animals, and we could not find an outside group repeating the human studies.

View Epithalon & get a quote →

From a cattle extract to a four-letter peptide

The name epithalamin first appeared in research in 1973, for a polypeptide extract taken from cattle pineal glands. According to a 2025 review in the International Journal of Molecular Sciences, the early work on it was led mainly by Vladimir Khavinson and Vladimir Anisimov in Russia.

Epitalon came later. It was built from the amino acid make-up of epithalamin, giving the short chain Ala-Glu-Asp-Gly, or AEDG for short. The review dates the patent on its synthesis to 2000, citing a Russian patent in Khavinson’s name. For years nobody had shown the tetrapeptide actually exists in the body. In 2017, a paper from Khavinson’s group reported finding it in a pineal polypeptide preparation for the first time.

Epithalon is usually filed with the short “bioregulator” peptides from the same school of research. Our bioregulators explainer covers that wider family, so here we stick to Epithalon itself.

The telomere story

Telomeres sit on the ends of chromosomes and protect them from damage. In normal cells they get shorter over time, and once they are critically short the cell stops dividing. Telomerase is the enzyme that builds telomeric DNA. It is absent in mature body cells, but switched back on in about 90% of human cancers, a detail worth holding onto. That is why a peptide linked to telomerase gets attention.

The key papers are from 2003 and 2004. Using human fetal lung fibroblasts, Khavinson’s team reported that Epithalon switched on telomerase activity and lengthened telomeres. In the follow-up, untreated fibroblasts stopped dividing after the 34th passage, the lab term for each round of splitting and regrowing a culture. Epithalon-treated cells were still dividing after the 44th.

In 2025 a group at Brunel University London, outside the Russian network, tested it in human cells. In normal fibroblasts and epithelial cells, telomeres grew longer, alongside more telomerase. In two breast cancer cell lines, telomeres grew too, partly through a different route called ALT. A correction to the paper was published later in 2025. The authors list their main limitation themselves: this was cells grown flat in a dish, and the next step is animal work.

See a batch COA before you order →

The record so far

Laid out side by side, the record is mixed, and the details matter more than the headlines.

The mouse line deserves a second look. In that study, run by the same research network, Epithalon did not change average lifespan, food intake or body weight, and overall tumour rates did not differ. For a peptide sold on a longevity story, its own mouse record includes a result where lifespan stayed put.

What exists in people

The review describes two human studies. The first, run at the St Petersburg Institute of Bioregulation and Gerontology and published by Khavinson and colleagues in 2002, examined 162 people with retinitis pigmentosa, an inherited eye disease, and compared Epithalon with conventional treatment. Improvements in retinal activity and visual fields were reported, with no side effects.

The second, published in 2021, looked at 75 women, with placebo and control groups included. A urine marker of melatonin production rose 1.6-fold against placebo, and the activity of several body-clock genes changed.

We could not find an independent repeat of either, and a ClinicalTrials.gov search for Epitalon or Epithalon in October 2026 returned no registered studies.

If you remember one thing: Epithalon’s telomere results are real lab findings, but they come mostly from one group, in cells and animals, and the mouse lifespan study came up flat.

Where the evidence stops

• One school of research. The telomerase, fruit fly, mouse and eye trial papers all list Khavinson as an author.
• Longer telomeres are not longer life. A change in a cell culture is a long way from an effect on ageing in a person.
• Lifespan results are patchy. Flies lived longer, but average lifespan did not change in the SHR mice.
• The cancer-cell finding needs care. The 2025 study found telomeres lengthened in breast cancer cell lines too, by another route.
• Thin human data. Two human studies described in the review, no registered trials, and no independent replication we could find.

A note on framing

Nothing here shows what Epithalon does in a person. Telomere length in a dish and lifespan in flies are measurements, not outcomes for people. We sell to researchers, and we would rather you read the papers than a forum thread.

Where JP fits

JP Research supplies Epithalon as research-grade freeze-dried powder, for laboratory research use only. We do not hold an independent lab report for Epithalon at the moment; you can request a COA from the product page, and our guide to reading a COA explains what to check. Orders are dispatched within 1 to 3 business days, with free courier across South Africa.

Browse the skin and longevity research range →

Sources

• Araj et al.: Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties (Int J Mol Sci, 2025)
• Al-dulaimi et al.: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (Biogerontology, 2025)
• ClinicalTrials.gov: search for Epitalon (no registered studies, October 2026)